Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients (Q89707188)
Jump to navigation
Jump to search
scientific article published on 13 February 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients |
scientific article published on 13 February 2020 |
Statements
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients (English)
Johan Askling
Joachim Burman
Katharina Fink
Anna Fogdell-Hahn
Martin Gunnarsson
Jan Hillert
Annette Langer-Gould
Jan Lycke
Petra Nilsson
Jonatan Salzer
Anders Svenningsson
Magnus Vrethem
Tomas Olsson
13 February 2020